What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · NVO

Weight-loss drug demand exploding — scoop up Novo Nordisk on the dip

Novo Nordisk's weight-loss pill just hit 3 million prescriptions, but the stock has been beaten down lately. Wall Street might be overlooking how fast demand is actually growing.

Idea

Novo Nordisk's Wegovy pill hitting 3 million prescriptions is a massive milestone showing real-world demand is surging. Despite this, the stock has been beaten down, creating a gap between the company's fundamental growth and its recent stock price. When a company's product is selling faster than ever but the stock is out of favor, it often presents a buying opportunity for patient investors.

Key details

NVO1D#healthcare#value#contrarian

Community

Upvotes

Views

Copies

Cosigns

News sources

Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? — Yahoo Finance

Related ideas

Alphabet looks cheap after doubling — analysts say there's more upside to catch
Bitcoin getting slammed by Japan rate fears and geopolitical panic — contrarian setup on crypto stocks
Chip stocks bounce on a scary market day — the bottom might be in

NVO trade ideas
Latest market news